Literature DB >> 28681318

Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.

Jusleen Ahluwalia1,2, Jeremy Udkoff3,4, Andrea Waldman3,4, Jenna Borok3,4, Lawrence F Eichenfield3,4.   

Abstract

Phosphodiesterase 4 (PDE4) is a cyclic AMP degrading enzyme in leukocytes. Several decades ago, increased PDE activity was demonstrated in patients with atopic dermatitis (AD). Currently, several PDE4 inhibitors in both topical and oral formulation have been developed to target the inflammatory cascade of AD. This review shows the pathogenic rationale behind these inhibitors, and discusses multiple PDE4 inhibitors that are under evaluation or in the market. PDE4 inhibitors may be considered as favorable agents in the repertoire of current interventions for AD.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28681318     DOI： 10.1007/s40265-017-0784-3

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  36 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

2.  Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Authors:  Amy S Paller; Wynnis L Tom; Mark G Lebwohl; Robin L Blumenthal; Mark Boguniewicz; Robert S Call; Lawrence F Eichenfield; Douglass W Forsha; William C Rees; Eric L Simpson; Mary C Spellman; Linda F Stein Gold; Andrea L Zaenglein; Matilda H Hughes; Lee T Zane; Adelaide A Hebert
Journal:  J Am Acad Dermatol       Date:  2016-07-11       Impact factor: 11.527

3.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Timothy G Berger; Alfons Krol; Amy S Paller; Kathryn Schwarzenberger; James N Bergman; Sarah L Chamlin; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Steven R Feldman; Jon M Hanifin; David J Margolis; Robert A Silverman; Eric L Simpson; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2014-05-09       Impact factor: 11.527

4.  A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.

Authors:  Linda F Stein Gold; Lynda Spelman; Mary C Spellman; Matilda H Hughes; Lee T Zane
Journal:  J Drugs Dermatol       Date:  2015-12       Impact factor: 2.114

5.  Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis.

Authors:  J M Butler; S C Chan; S Stevens; J M Hanifin
Journal:  J Allergy Clin Immunol       Date:  1983-05       Impact factor: 10.793

6.  Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.

Authors:  Masutaka Furue; Yasumi Kitahara; Hideto Akama; Seiichiro Hojo; Nobukazu Hayashi; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2014-06-18       Impact factor: 4.005

Review 7.  Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

Authors:  Sunanda G Dastidar; Deepa Rajagopal; Abhijit Ray
Journal:  Curr Opin Investig Drugs       Date:  2007-05

Review 8.  Systemic Agents for Severe Atopic Dermatitis in Children.

Authors:  Eliza R Notaro; Robert Sidbury
Journal:  Paediatr Drugs       Date:  2015-12       Impact factor: 3.022

9.  Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.

Authors:  Tsugunobu Andoh; Tetsuro Yoshida; Yasushi Kuraishi
Journal:  Exp Dermatol       Date:  2014-05       Impact factor: 3.960

10.  Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.

Authors:  Lee T Zane; Leon Kircik; Robert Call; Eduardo Tschen; Zoe Diana Draelos; Sanjay Chanda; Merrie Van Syoc; Adelaide A Hebert
Journal:  Pediatr Dermatol       Date:  2016-05-18       Impact factor: 1.588
View more
  6 in total

1.  Identification of a PDE4-Specific Pocket for the Design of Selective Inhibitors.

Authors:  Xiaoqing Feng; Huanchen Wang; Mengchun Ye; Xue-Tao Xu; Ying Xu; Wenzhe Yang; Han-Ting Zhang; Guoqiang Song; Hengming Ke
Journal:  Biochemistry       Date:  2018-07-17       Impact factor: 3.162

2.  Childhood atopic dermatitis: current developments, treatment approaches, and future expectations

Authors:  Pınar Gür Çetinkaya; Ümit Murat Şahiner
Journal:  Turk J Med Sci       Date:  2019-08-08       Impact factor: 0.973

Review 3.  The Biological Effects of Forsythia Leaves Containing the Cyclic AMP Phosphodiesterase 4 Inhibitor Phillyrin.

Authors:  Sansei Nishibe; Kumiko Mitsui-Saitoh; Junichi Sakai; Takahiko Fujikawa
Journal:  Molecules       Date:  2021-04-19       Impact factor: 4.411

Review 4.  An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.

Authors:  Letizia Crocetti; Giuseppe Floresta; Agostino Cilibrizzi; Maria Paola Giovannoni
Journal:  Molecules       Date:  2022-08-04       Impact factor: 4.927

5.  Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.

Authors:  H Saeki; N Baba; K Ito; D Yokota; H Tsubouchi
Journal:  Br J Dermatol       Date:  2021-11-01       Impact factor: 11.113

Review 6.  Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.

Authors:  Heng Li; Jianping Zuo; Wei Tang
Journal:  Front Pharmacol       Date:  2018-10-17       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.